Molecular Characterization of Rifampicin-Resistant Staphylococcus aureus Isolates from Retail Foods in China

Jiahui Huang 1,†, Feng Zhang 1,2,†, Jumei Zhang 1, Jingsha Dai 1, Dongli Rong 1, Miao Zhao 1, Juan Wang 1, Yu Ding 1,‡, Moutong Chen 1, Liang Xue 1, Qihui Gu 1, Shi Wu 1,* and Qingping Wu 1,⁎

1 Guangdong Provincial Key Laboratory of Microbial Safety and Health, State Key Laboratory of Applied Microbiology Southern China, Key Laboratory of Agricultural Microbiomics and Precision Application, Ministry of Agriculture and Rural Affairs, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510070, China; jiahui0418@163.com (J.H.); zfloveissun@163.com (E.Z.); zhangjm926@126.com (J.Z.); dajis@gdim.cn (J.D.); rongdl69@126.com (D.R.); zm93032@163.com (M.Z.); wangiujan@scau.edu.cn (J.W.); dingyu@jnu.edu.cn (Y.D.); cmtoons@hotmail.com (M.C.); xueliang@gdim.cn (L.X.); guqh888@163.com (Q.G.)
2 School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
* Correspondence: wushiloveyou@126.com (S.W.); wuqp203@163.com (Q.W.); Tel./Fax: +86-20-8768-0942 (S.W.); +86-20-8768-8132 (Q.W.)
† Authors contributed equally to this work.

Abstract: This study investigated the molecular characteristics of rifampicin-resistant (RIF-R) Staphylococcus aureus isolates recovered from 4300 retail food samples covering most provincial districts in China, from 2011 to 2016. Of the 1463 S. aureus enrolled, 149 isolates (142 MSSA and 7 MRSA) were identified as rifampicin-resistant, including 20 high-level (MICs ≥ 8 µg/mL) and 129 low-level (MICs between 2 and 4 µg/mL) rifampicin-resistant strains. Most of the RIF-R S. aureus isolates were resistant to more than three antibiotics. The mutations in the rifampicin resistance-determining region of the rpoB gene were studied in all RIF-R strains. All of the strains presented the mutational change 481 His/Asn and five isolates presented an additional mutation, including 477 Asp/Tyr, 527 Ile/Met, and 466 Leu/Ser, respectively. Thirteen STs and twenty-one spa types were represented, in which five MRSA showed non-type SCCmec and the remaining MRSA belonged to SCCmec type IV—where, ST1-t127 was the predominant type from all of the isolates, while ST398-t034 was the predominant type for the MRSA isolates. In this study, we found that the food-related RIF-R S. aureus may have a unique genetic background selection. However, the scenario regarding the presence of RIF-R S. aureus, especially MRSA, in retail food in China is not favorable and warrants public attention.

Keywords: Staphylococcus aureus; MRSA; rifampicin resistance; rpoB gene; MLST

1. Introduction

Staphylococcus aureus is a versatile pathogens capable of causing nosocomial and community-acquired infections [1]. It is one of the most important foodborne microorganisms, for which its pathogenicity affects human’s health through staphylococcal enterotoxins (SEs). The first food poisoning event caused by staphylococci occurred in 1884 [2]. Recently, it has been found in food producing chains, for example the equipment used for the production of food and in contaminated ingredients and so on [3,4]. Between 2000 and 2015, S. aureus was one of the most frequently reported pathogens in ready-to-eat (RTE) food (such as cheeses, cured meats, sausages, smoked fishes, salads, and so on) in Africa and Europe [5–7]. In China, the prevalence of S. aureus-contaminated retail food increased over time [8].

Rifampicin (RIF) is the most used broad-spectrum antibiotic against bacterial pathogens. It has a potent bactericidal activity, good tissue penetration and modest activity against non-growing cells [9]. RIF is currently indicated in combination therapy for implant-associated...
infections, serious *S. aureus* infections, and has been shown to broaden the coverage of vancomycin-intermediate *S. aureus* (VISA) when used in combination with linezolid or daptomycin [10]. However, the long-term use of RIF, as well as, its use as a monotherapy, has been shown to be associated with the development of RIF-resistant (RIF-R) *S. aureus*. Nowadays, many researchers have suggested that the major reason for RIF resistance is the mutations, mainly single nucleotide polymorphisms (SNPs), in the *rpoB* gene shown in the *Staphylococcus* species [11–13]. One of the first report suggested that *rpoB* gene mutations involving eight conserved amino acids were identified in RIF-R *Mycobacterium tuberculosis*. All mutations were clustered within a region of 23 amino acids [14]. This conclusion was further verified in RIF-resistance *Staphylococci* [11,15]. The β-subunit of the bacterial RNA polymerase, encoded by the *rpoB* gene, plays an important role in RIF inhibition [11]. In *S. aureus*, a number of studies have revealed a worrying link between certain *rpoB* mutations and decreased susceptibility not only to RIF, but also to other last-line anti-MRSA antibiotics such as vancomycin, daptomycin, β-lactams, and imipenem [16–20].

In our previous study, we collected 4300 retail food samples from supermarkets, fairs, and farmers’ markets. We covered most of the provincial capitals of China from July 2011 to June 2016 and collected 1463 *S. aureus* isolates from 1063 positive samples from all of the sampling sites [21,22]. Furthermore, most of *S. aureus* isolates from retail food showed severe antibiotic resistance [22–25]. However, there were a limited number of reported studies on RIF-R *S. aureus* isolated from retail food. In order to better understand the epidemic background and the molecular characters in RIF-R isolates for *S. aureus* in food, this study re-identified the RIF-R *S. aureus* in food-related isolates and further studied RIF-R *S. aureus* in terms of the following: (1) the mutations in the *rpoB* gene that contributed to RIF resistance, and (2) the antimicrobial resistance profiles and their genotypic types (MLST and *spa* typing).

### 2. Results

#### 2.1. Distribution of Rifampicin-Resistant *S. aureus* from Retail Foods in China

In total, 149 RIF-R *S. aureus* isolates, including 7 MRSA strains, were re-identified by the disk diffusion method and were used for the present study. The RIF-R *S. aureus* isolates represented 10.2% of all *S. aureus* isolates. The origin of the strains was mainly from raw meat, aquatic products, quick-frozen products, and RTE food, including 35 (8.4%) of the 419 isolates from raw meat, 45 (9.5%) of the 473 isolates from aquatic products, 43 (12.0%) of the 358 isolates from quick-frozen products, 22 (16.8%) of the 131 isolates from ready-to-eat food, 1 (2.4%) of the 41 isolates from edible mushrooms, and 3 (25.0%) of the 12 isolates from pasteurized milk, whereas vegetables were free of RIF-R *S. aureus* isolates (Table 1). The RIF-R MRSA isolates were distributed in raw meat (n = 4), aquatic products (n = 1), quick-frozen products (n = 1), and RTE food (n = 1). The prevalence of RIF-R MSSA in foods was significantly higher than RIF-R MRSA (*p* < 0.001, \(\chi^2\) test).

| Types of Product | No. of *S. aureus* | No. (%) of RIF-R *S. aureus* Isolates | No. (%) of RIF-R MRSA | No. (%) of RIF-R MSSA | *p*-Value \(\Delta\) |
|------------------|---------------------|---------------------------------------|-----------------------|-----------------------|-----------------|
| Raw meat         | 419                 | 35 (8.4)                              | 4 (1.0)               | 31 (7.4)              | <0.01           |
| Aquatic products | 473                 | 45 (9.5)                              | 1 (0.2)               | 44 (9.3)              | <0.01           |
| Quick-frozen meat| 358                 | 43 (12.0)                             | 1 (0.3)               | 42 (11.7)             | <0.01           |
| Ready-to-eat food| 131                 | 22 (16.8)                             | 1 (0.8)               | 21 (16.0)             | <0.01           |
| Edible mushrooms | 41                  | 1 (2.4)                               | 0 (0.0)               | 1 (2.4)               | <0.01           |
| Vegetables       | 29                  | 0 (0.0)                               | 0 (0.0)               | 0 (0.0)               | NA \(\Delta\)   |
| Pasteurized milk | 12                  | 3 (25.0)                              | 0 (0.0)               | 3 (25.0)              | <0.01           |
| Total            | 1463                | 149 (10.2)                            | 7 (0.5)               | 142 (9.7)             | <0.01           |

\(\Delta\) RIF-R MRSA vs. MSSA by the Chi-squared test (two-sided); \(\Delta\) NA—not applicable.
2.2. Antibiotic Resistance of Rifampicin-Resistant S. aureus Isolates

The antibiotic susceptibility results of 149 RIF-R S. aureus isolates are shown in Table 2. In this study, most of RIF-R S. aureus isolates were resistant to more than three antibiotics, whereas only 9.4% of isolates were resistant to 0–3 antibiotics. For multidrug resistance isolates, 77.9% of isolates were resistant to 4–10 antibiotics, 10.7% of isolates were resistant to 11–15 antibiotics, and 2.0% of isolates were resistant to 16–24 antibiotics. The isolates were susceptible to linezolid and teicoplanin, and the frequencies of resistance to individual agents were 94.6% for ampicillin and 92.6% for penicillin G, followed by 75.8% for kanamycin, 53.7% for erythromycin, 49% for tetracycline, 30.2% for clindamycin, 28.9% for gentamicin, 26.8% for telithromycin, 26.2% for norfloxacin, 24.8% for fusidic acid, 18.1% for ciprofloxacin, 16.1% for streptomycin, 10.7% for chloramphenicol, 6.7% for amikacin, 6.7% for trimethoprim/sulphamethoxazole 1:19, 5.4% for ceftazidime, 4.7% for cefoxitin, 4.0% for cefepime, 3.4% for quinupristin/dalfopristin, and 2.0% for nitrofurantoin. Only seven RIF-R S. aureus isolates belonged to MRSA, whereas most of RIF-R S. aureus isolates were MSSA (Table 1). Interestingly, the RIF-R MRSA isolates showed multi-drug resistance to more than 10 antibiotics in 71.4% of cases (five out of seven isolates). Rates of resistance to AMC, FEP, CAZ, GEN, CHL, CLI, TEL, SXT, and NIT, and intermediate resistance to RIF were all significantly higher in the MRSA group than in the MSSA group ($p < 0.01$, $\chi^2$ test) (Table 2). In total, the MDR rate for MRSA isolates was significantly higher than that for MSSA ($p < 0.01$, $\chi^2$ test).

Table 2. Results of antimicrobial susceptibility tests of 149 RIF-R S. aureus isolates obtained from retail food in China.

| Antibiotics | RIF-R S. aureus (n = 149) | RIF-R MRSA (n = 7) | RIF-R MSSA (n = 142) | $p$-Value $^b$ |
|-------------|------------------------|------------------|----------------------|----------------|
|             | NO. of R (%) | NO. of I (%) | NO. of R (%) | NO. of I (%) | NO. of R (%) | NO. of I (%) |
| AMC         | 10 (6.7)    | -              | 6 (85.71) | -              | 4 (2.82) | -              |
| AMP         | 141 (94.6)  | -              | 7 (100)   | -              | 134 (94.37) | -              |
| FEP         | 6 (4.0)     | 2 (1.3)        | 5 (71.43) | 2 (28.57)     | 1 (0.7) | 0 (0.0)       |
| FOX         | 7 (4.7)     | -              | 7 (100)   | -              | 0 (0.0) | -              |
| PEn         | 138 (92.6)  | -              | 7 (100)   | -              | 131 (92.25) | -              |
| CAZ         | 8 (5.4)     | 23 (15.4)      | 7 (100)   | 0 (0.0)       | 1 (0.7) | 23 (16.20)    |
| AMK         | 10 (6.7)    | 51 (34.2)      | 1 (14.29) | 3 (42.86)     | 9 (6.34) | 48 (33.80)    |
| GEN         | 43 (28.9)   | 0 (0.0)        | 5 (71.43) | 0 (0.0)       | 38 (26.76) | 0 (0.0)       |
| KAN         | 113 (75.8)  | 11 (7.4)       | 5 (71.43) | 1 (14.29)     | 108 (76.06) | 10 (7.04)     |
| STR         | 24 (16.1)   | 103 (69.1)     | 4 (57.14) | 2 (28.57)     | 20 (14.08) | 101 (71.3)    |
| CHL         | 16 (10.7)   | 27 (18.1)      | 4 (57.14) | 0 (0.0)       | 12 (8.45) | 27 (19.01)    |
| CLI         | 45 (30.2)   | 16 (10.7)      | 6 (85.71) | 0 (0.0)       | 39 (27.46) | 16 (11.27)    |
| ERY         | 80 (53.7)   | 16 (10.7)      | 7 (100)   | 0 (0.0)       | 73 (51.41) | 16 (11.27)    |
| TEL         | 40 (26.8)   | 27 (18.1)      | 6 (85.71) | 1 (14.29)     | 34 (23.94) | 26 (18.31)    |
| CIP         | 27 (18.1)   | 31 (20.8)      | 4 (57.14) | 1 (14.29)     | 23 (16.20) | 30 (21.13)    |
| NOR         | 39 (26.2)   | 11 (7.4)       | 4 (57.14) | 0 (0.0)       | 35 (24.65) | 11 (7.75)     |
| TET         | 73 (49.0)   | 5 (3.4)        | 5 (71.43) | 0 (0.0)       | 68 (47.89) | 5 (3.52)      |
| LZD         | 0 (0.0)     | -              | 0 (0.0)   | -              | NA      | NA            |
| RIF         | 122 (81.9)  | 27 (18.1)      | 4 (57.14) | 3 (42.86)     | 118 (83.10) | 24 (16.90)    |
| SXT         | 10 (6.7)    | 2 (1.3)        | 4 (57.14) | 0 (0.0)       | 6 (4.23) | 2 (1.41)      |
| QD          | 5 (3.4)     | 11 (7.4)       | 0 (0.0)   | 1 (14.29)     | 5 (3.52) | 10 (7.04)     |
| TEC         | 0 (0.0)     | 42 (28.2)      | 0 (0.0)   | 2(28.57)      | 0 (0.0) | 40 (28.17)    |
| NIT         | 3 (2.0)     | 18 (12.1)      | 2 (28.57) | 0 (0.0)       | 1 (0.7) | 18 (12.68)    |
| FD          | 37 (24.8)   | -              | 2 (28.57) | 0 (0.0)       | 35 (24.65) | 0 (0.0)       |

0–3 Antimicrobial | 14 (9.4) | - | 0 (0.0) | - | 14 (9.9) | - |
4–10 Antimicrobial | 116 (77.9) | 2 (8.6) | 114 (80.2) | - | - | - |
11–15 Antimicrobial | 16 (10.7) | 2 (8.6) | 14 (9.9) | - | - | - |
16–24 Antimicrobial | 3 (2.0) | 3 (42.8) | 0 (0.0) | - | - | - |

R: Resistant; I: Intermediate; NA: not applicable. $^a$ AMC: Amoxicillin/clavulanic acid; AMP: Ampicillin; FEP: Cefepime; FOX: Cefoxitin; PEN: Penicillin G; CAZ: Ceftazidime; AMK: Amikacin; GEN: Gentamicin; KAN: Kanamycin; STR: Streptomycin; CHL: Chloramphenicol; CLI: Clindamycin; ERY: Erythromycin; TEL: Telithromycin; CIP: Ciprofloxacin; NOR: Norfloxacin; TET: Tetracycline; LZD: Linezolid; RIF: Rifampicin; SXT: Trimethoprim/sulphamethoxazole 1:19; QU: Quinupristin/dalfopristin; TEC: Teicoplanin; NIT: Nitrofurantoin; FD: Fusidic acid; $^b$ Antibiotic resistance of MRSA vs. MSSA using the Chi-squared test (two-sided). $^c$ Rifampicin-intermediate of MRSA vs. MSSA using the Chi-squared test (two-sided).
2.3. Rifampicin Resistance Levels and Associated rpoB Mutations

Among the 149 RIF-R S. aureus isolates, 129 isolates showed a low level of RIF resistance (MICs between 2 and 4 µg/mL) and 20 isolates showed a high level of RIF resistance (MIC > 8 µg/mL). In addition, three out of seven MRSA showed a high level of RIF resistance (MIC > 16 µg/mL). The mutations in the RIF resistance-determining region of the rpoB gene were studied in all 149 RIF-R strains. The results are shown in Table 3. All 149 strains presented the mutational change 481 His/Asn, determined by a mutation in cluster I of the rpoB gene, conferring a low-level of RIF resistance. Three additional mutations were found in five isolates, including 477 Asp/Tyr (n = 3), 527 Ile/Met (n = 1), and 466 Leu/Ser (n = 1). Of these, two isolates with MIC ≥ 16 µg/mL had an additional amino acid substitution: 466 Leu/Ser (n = 1) or 527 Ile/Leu (n = 1), associated with a high level of RIF resistance.

Table 3. The characteristics of the RIF-R S. aureus isolates studied.

| Nucleotide Mutation | Amino Acid Substitution | Mutation Types | RIF MIC (µg/mL) | Number of Isolates |
|---------------------|-------------------------|---------------|-----------------|--------------------|
| CAT → AAT           | His481/Asn              | cluster I     | 2               | 77                 |
| CCA → ACA, CAT → AAT| Asp473/Tyr, His481/Asn | cluster I     | 2               | 1                  |
| CAT → AAT           | His481/Asn              | cluster I     | 4               | 51                 |
| CCA → ACA, CAT → AAT| Asp473/Tyr, His481/Asn | cluster I     | 4               | 2                  |
| CAT → AAT           | His481/Asn              | cluster I     | 16              | 3                  |
| CAT → AAT           | His481/Asn              | cluster I     | >16             | 5                  |
| CAT → ATT, TAA → GAA| His481/Asn, Ile527/Met  | cluster I, cluster II | >128             | 1                  |
| CAT → ATT, CAT → AAT| Leu466/Ser, His481/Asn | cluster I     | >128            | 1                  |

2.4. Distribution of Molecular Types

MLST and spa typing were carried out in all 149 RIF-R S. aureus strains. The results are shown in Table 4. Among these isolates, a total of 13 STs and 21 spa types were represented (except sta43-0 and sta43-2 were shown to be on-type). The predominant MLST types were ST1 (97/149, 65.1%), followed by ST72 (15/149, 10.1%), ST5 (11/149, 7.4%), ST398 (10/149, 6.7%), ST12 (5/149, 3.4%), and ST45 (4/149, 2.7%), and the seven singletons included ST25, ST59, ST2592, ST4449, ST4470, ST4472, and ST9. The most commonly observed spa type was t127 (90/149, 60.4%), followed by t3092 (15/149, 10.1%), t002 (9/149, 6.0%), t034 (9/149, 6.0%), t123 (4/149, 2.7%), t116 (2/149, 1.3%), and t5500 (2/149, 1.3%), and the 12 singletons included t1381, t17635, t1908, t2207, t2459, t2720, t559, t9472, t17632, t17887, t163, and t899. There were 27 different ST-spa types in this research combining the STs and spa types, of which ST398-t034 was the predominant type (3/7, 42.9%) of MRSA isolate, whereas ST1-t127 was the predominant type (96/142, 67.6%) of MSSA isolate in RIF-R S. aureus (Table 4). Only ST1 MRSA (n = 1) and ST45 MRSA (n = 1) harbored SCCmec type IV.

Table 4. Molecular features of RIF-R S. aureus isolates.

| STs (No.) | spa Types (No.) | Nucleotide Mutation | Amino Acid Substitution | Mutation Types |
|-----------|-----------------|---------------------|-------------------------|---------------|
| t127 (82) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t1381 (1) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t17635 (1)|                 | CAT → AAT           | His481/Asn              | cluster I     |
| t177 (2)  |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t1908 (1) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t2207 (1) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t2459 (1) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t2720 (1) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t5500 (2) |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t559 (1)  |                 | CAT → AAT           | His481/Asn              | cluster I     |
| t127 (1)  |                 | CAT → AAT, CAT → AAT| Leu466/Ser, His481/Asn | cluster I     |
| t127 (3)  |                 | CCA → ACA, CAT → AAT| Asp473/Tyr, His481/Asn | cluster I     |
Table 4. Cont.

| STs (No.) | spa Types (No.) | Nucleotide Mutation | Amino Acid Substitution | Mutation Types |
|-----------|-----------------|----------------------|-------------------------|----------------|
| ST72 (15) | t3092 (15)      | CAT → AAT            | His481/Asn              | cluster I      |
| ST5 (11)  | t002 (9)        | CAT → AAT            | His481/Asn              | cluster I      |
|           | non type (2)    | CAT → AAT            | His481/Asn              | cluster I      |
| ST398 (10)| t034 (9)        | CAT → AAT            | His481/Asn              | cluster I      |
|           | t9472 (1)       | CAT → AAT            | His481/Asn              | cluster I      |
| ST12 (5)  | t213 (4)        | CAT → AAT            | His481/Asn              | cluster I      |
| ST45 (4)  | t17632 (1)      | CAT → AAT            | His481/Asn              | cluster I      |
| ST25 (1)  | t17987 (1)      | CAT → AAT            | His481/Asn              | cluster I      |
| ST59 (1)  | t163 (1)        | CAT → AAT            | His481/Asn              | cluster I      |
| ST2592 (1)| t127 (1)        | CAT → AAT            | His481/Asn              | cluster I      |
| ST4449 (1)| t127 (1)        | CAT → AAT            | His481/Asn              | cluster I      |
| ST4470 (1)| t127 (1)        | CAT → AAT            | His481/Asn              | cluster I      |
| ST4472 (1)| t127 (1)        | CAT → AAT            | His481/Asn              | cluster I      |
| ST9 (1)   | t899 (1)        | CAT → AAT, TAA → GAA | His481/Asn, Ile527/Met  | cluster I, cluster II |

3. Discussion

In recent years, the frequency of the RIF-R S. aureus isolated from clinics in China has increased rapidly, showing that the percentage of RIF-R MRSA isolates was only 15.5% in 2004, but increased rapidly to 50.2% in 2008 [26,27]. However, studies on RIF-R S. aureus isolated from retail food have rarely been reported in China. In this study, a total of 149 food-related S. aureus isolates (10.2%) were identified as RIF-R isolates, which covered all types of animal-derived food, including raw meat, aquatic products, quick-frozen products, and RTE food. Recently, Şanlıbaba P. (2022) collected 96 S. aureus strains from retail raw beef, sheep and lamb meat in Turkey, and 8.33% of strains were found to be resistant to RIF [28]. In Portugal, only one RIF-R S. aureus was detected in various foods [29]. In north-western Greece, only 1.6% RIF-R S. aureus was found in dairy products [30]. Compared with these studies, the prevalence rate of RIF-R S. aureus isolates in food the food we examined in China was not low, which should be brought to public attention.

RIF acts by interacting specifically with the β-subunit of the bacterial RNA polymerase encoded by the rpoB gene [31,32]. Many previous studies have reported that the mutations of rpoB were a response to RIF resistance in bacteria such as Escherichia coli [33], Mycobacterium leprae [34], Streptococcus pneumoniae [35], and Neisseria meningitides [36]. In this study, we also amplified and sequenced the portions of rpoB of RIF-R S. aureus isolates in food. It was found that all strains presented the mutational change 481 His/Asn. In China, Zhou et al. (2012) collected 88 RIF-R MRSA isolates from clinical specimens in the Microbiology Department of Anhui Provincial Hospital in China, and found that the mutation at 481 His/Asn was the most common in 95.5% of RIF-R isolates [37]. Similarly, this is consistent with Liang’s research, showing 481 His/Asn mutations of rpoB in all RIF-R or intermediate-resistant isolates from women and children in Guangzhou, China [38]. Interestingly, as described in previous literature, the position of 481 RpoB presents a hot-spot for amino acid residue replacement and has recently been found to be the strongest genetic marker of increased vancomycin resistance [26,39,40]. Therefore, the scenario regarding the presence of RIF-R S. aureus, especially MRSA in retail food in China, should warrant public attention. Moreover, as previously described, a high-level resistance of RIF may also be attributed to additional mutations within rpoB [41]. Isolates containing multiple mutations also showed high-level RIF resistance [42]. According to Zhou et al. (2012), it was found that 87.5% RIF-R S. aureus had an additional mutation 466 Leu/Ser and the RIF resistance level was higher [37]. In our study, fewer strains had additional mutations, such as 527 Ile/Met and 466 Leu/Ser mutations, which was also associated with a higher-level of resistance of RIF. Although the rate of multiple mutations was not high, it should be paid attention.
In this study, it was found that most RIF-R \textit{S. aureus} isolated from retail food belonged to ST1-t127. Meanwhile, ST398-t034 was the predominant type of MRSA isolate. This is different from the predominant types of food-related MRSA, which, when isolated simultaneously with RIF-R strains, showed that the predominant type was ST59-t437 \[22\]. According to previous studies, the predominant types of clinical RIF-R strains were ST239 or ST45 \[37,38,43,44\]. In 2018, Liang et al. collected 131 \textit{S. aureus} isolated from patients in four centers for women and children in Guangzhou, and found that CC59 (ST59-IV, 48.8%; ST338-III, 35.7%) was a major clone (84.4%) among the MRSA isolates, but 93.8% of the RIF-R or intermediate resistant isolates belonged to ST45 \[38\]. Thus, the RIF-R \textit{S. aureus} in the food may have a unique genetic background selection. However, the reasons for this specific selection need to be further explored.

As we know, RIF is an important antibiotic used in combination therapy for the treatment of deep-seated staphylococcal infections \[45\]. This review also provided evidence that RIF combined with trimethoprim/sulfamethoxazole and minocycline is associated with a high rate of isolation of \textit{S. aureus} resistance, whereas RIF combined with other agents is associated with lower rates of resistance \[46\]. Furthermore, a combination therapy, with an antibiotic such as vancomycin, is often required in order to reach deep-seated infections effectively \[47\]. Thus, resistance to RIF can make the treatment of \textit{S. aureus} infection, especially MRSA infection, more difficult. Except for RIF, antibiotics such as ampicillin, penicillin, kanamycin, erythromycin, and tetracycline, are common drugs used for \textit{S. aureus} infection \[48\]. However, the resistance rates of these antibiotics for RIF-R \textit{S. aureus} exceeded 50% in this study. Moreover, most of the RIF-R \textit{S. aureus} isolates were resistant to more than three antibiotics. Of which, 19 RIF-R \textit{S. aureus} isolates were resistant to more than 10 antibiotics, namely 5 MRSA and 14 MSSA. Interestingly, ST398 MRSA and MSSA (36.8%, 7/19) were the predominant types of multi-drug resistant isolates in RIF-R \textit{S. aureus}. As we know, MRSA CC398 is a frequent colonizer of humans with occupational exposure to livestock \[49\]. Recently, infections caused by MSSA ST398 have been described in humans \[50–52\] and it has been shown to cause infections more frequently than MRSA ST398 \[21\]. In 2011, Argudín et al. studied the resistance determinants of German \textit{S. aureus} ST398 isolates from non-human sources, and found that none of the isolates were resistant to RIF \[53\]. Thus, further investigation is required to elucidate the emergence of multidrug-resistant ST398 in RIF-R \textit{S. aureus}.

4. Materials and Methods

4.1. Bacterial Strains

A total of 1463 \textit{S. aureus} were isolated from 4300 retail food products between July 2011 and June 2016. The samples were collected from supermarkets, fairs, and farmers’ markets, which covered most of the provincial capitals of China in 39 cities (Figure S1). One hundred samples were collected from each city, except for Guangzhou, where 500 samples were collected. These strains were isolated from seven types of food products, including 419 isolates from meat and meat products (bacon/sausage, poultry, pork, mutton, and beef), 473 isolates from aquatic products (freshwater fish, shrimp, and seafood), 358 isolates from quick-frozen products (frozen dumplings/steamed stuffed buns and frozen meat), 131 isolates from ready-to-eat (RTE) food (cold vegetable/noodle dishes in sauce, fried rice/sushi, roast meat, sausage, and ham), 41 isolates from edible mushrooms, 29 isolates from vegetables, and 12 isolates from pasteurized milk. These isolates were obtained according to the GB 4789.10-2010 food microbiological examination of \textit{S. aureus} (National Food Safety Standards of China) and the most probable number (MPN) method \[54\]. The \textit{S. aureus} isolates were streaked onto chromogenic \textit{S. aureus} agar plates (Huankai) and were re-identified by Gram’s staining, microscopic examination, coagulase testing, and catalase testing. MRSA was initially screened by the cefoxitin disk diffusion method, and then confirmed by polymerase chain reaction (PCR) detecting \textit{meca}.
4.2. Antimicrobial Susceptibility Testing

All isolates were tested for antimicrobial susceptibility by the disk diffusion method using Mueller−Hinton agar and commercially available discs (Oxoid, Basingstoke, UK). The antimicrobial agents used were amoxycillin/clavulanic acid (30 µg), ampicillin (10 µg), cefepime (10 µg), cefoxitin (30 µg), amikacin (30 µg), gentamicin (10 µg), kanamycin (30 µg), streptomycin (25 µg), chloramphenicol (30 µg), clindamycin (2 µg), erythromycin (15 µg), telithromycin (15 µg), ciprofloxacin (5 µg), norfloxacin (10 µg), tetracycline (30 µg), linezolid (30 µg), trimethoprim/sulphamethoxazole 1:19 (25 µg), rifampicin (5 µg), quinupristin/dalfopristin (15 µg), teicoplanin (30 µg), nitrofurantoin (300 µg), and fusidic acid (10 µg). *Staphylococcus aureus* ATCC25923 and *Escherichia coli* ATCC25922 were used as the quality control organisms [55]. The MICs of rifampicin for all *S. aureus* isolates were further determined using the agar dilution method. The results of the antimicrobial susceptibilities of the analyzed strains were scored according to the guidelines of the CLSI [55].

4.3. Detection of Rifampicin Resistance-Associated Mutations

All of the isolates were incubated at 37 °C overnight on BHI (brain heart infusion broth). Genomic DNA was extracted using a Genomic DNA Extraction Kit (Magen Biotech, Guangzhou, China) according to the manufacturer’s instructions. The concentration of the genomic DNA was determined at 260 nm using a NanoDrop ND-1000 UV−VIS spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). An internal sequence of gene *rpoB* of 432 bp (nucleotides 1216 to 1648) was amplified by PCR. This region included the RIF resistance determining cluster I (nucleotides 1384–1464, amino acid number 462–488) and cluster II (nucleotides 1543–1590, amino acid number 515–530). The amplification was carried out in 149 RIF-R strains. Amplification was carried out as previously described [56]. The PCR products were purified and analyzed by DNA sequencing. The nucleotide sequences obtained were compared to the *rpoB* wild type sequence from *S. aureus* subsp. aureus (GenBank accession number: X64172) using the clustalw software (http://www.ebi.ac.uk/tools/clustalw/index.html, accessed 5 June 2019).

4.4. Molecular Typing

4.4.1. *spa*-Typing

Sequence typing of the *S. aureus* protein A (*spa*) repeat region was amplified according to a published protocol [57]. All isolates were analyzed using the primers spa-1113f (5′-TAAAGACGATCCTTCGGTGAGC-3′) and spa-1514r (5′-CAGCAGTAGTGCCGTTTGCTT-3′). The PCR amplification conditions were as follows: an initial cycle of 80 °C for 5 min; 35 cycles of 94 °C for 45 s, 60 °C for 45 s, 72 °C for 2 min, and a final extension at 72 °C for 10 min. The *spa* types were randomly assigned using the Spa Server website (http://spaserver2.ridom.de, accessed 10 July 2019).

4.4.2. Multilocus Sequencing Typing

The MLST scheme used to characterize *S. aureus* isolates is based on the sequence analysis of the following seven housekeeping genes: *arcC* (Carbamate kinase), *aroE* (Shikimate dehydrogenase), *glpF* (Glycerol kinase), *gmk* (Guanylate kinase), *pta* (Phosphate acetyltransferase), *tpi* (Triosephosphate isomerase), and *yqil* (Acetyl coenzyme A acetyltransferase) [58]. The PCR amplification conditions were as follows: an initial cycle of 94 °C for 5 min, 35 cycles of 94 °C for 45 s, 60 °C for 45 s, 72 °C for 2 min, and a final extension at 72 °C for 10 min. The DNA fragments were purified using a PCR purification kit (Qiagen, Hilden, Germany) and were sequenced in each direction with Big Dye fluorescent terminators on an ABI 3730XL sequencer (Applied BioSystems, Foster, USA). For each MLST locus, an allele number was given to each distinct sequence variant, and a distinct sequence type (ST) number was attributed to each distinct combination of alleles at the seven genes. Sequence types (STs) were determined by using the *Staphylococcus aureus* MLST database (https://pubmlst.org/saureus/, accessed 20 July 2019). Sequence Type Analysis and Re-
combinational Tests software (S.T.A.R.T. ver.2; http://pubmlst.org/software/analysis/start2, accessed 25 July 2019) was used to analyze the data of MLST.

### 4.4.3. SCCmec Typing

The SCC\textit{mec} typing method was performed on the isolates by multiplex PCR, as previously described [59]. The PCR amplification conditions had an initial denaturation step at 94 °C for 5 min, followed by 10 cycles of 94 °C for 45 s, 65 °C for 45 s, and 72 °C for 1.5 min and another 25 cycles of 94 °C for 45 s, 55 °C for 45 s, and 72 °C for 1.5 min, ending with a final extension step at 72 °C for 10 min and followed by a hold at 4 °C. All PCR assay runs incorporated a reagent control (without template DNA). The PCR amplicons were visualized using a UV light box after electrophoresis on a 2% agarose gel containing 0.5 g/mL ethidium bromide.

### 4.5. Statistical Analysis

Statistical analyses were performed using SPSS 17.0 Data Editor (SPSS, Inc., Chicago, IL, USA). Categorical variables were described using frequencies and their proportion, and were compared using the Chi-square ($\chi^2$) test. $p < 0.05$ was considered to indicate a statistically significant difference.

## 5. Conclusions

In summary, we investigated food-related RIF-R \textit{S. aureus} and determined its genetic background in China in this study. RIF-R \textit{S. aureus} isolates were observed in most animal-derived types of food samples and rare in other types of food. Most of the RIF-R \textit{S. aureus} isolates showed multiple resistance and the reason for RIF resistance in \textit{S. aureus} is closely associated with the mutations that occur in the rpoB gene. This study indicated that the RIF-R \textit{S. aureus} in food may have a unique genetic background selection. However, monitoring of the emergence and possible dissemination of the MRSA ST398 strains among food-related infections for RIF treatment is warranted.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/antibiotics10121487/s1, Figure S1: The locations of the sampling sites for this study in China.

**Author Contributions:** Conceived and designed the experiments: Q.W., S.W. and J.Z. Performed the experiments: J.H. and F.Z. Analyzed the data: J.H., J.D., D.R., M.Z. and L.X. Contributed reagents/materials/analysis tools: Q.G., M.C., Y.D. and J.W. Contributed to the writing of the manuscript: J.H., S.W. and Q.W. All authors have read and agreed to the published version of the manuscript.

**Funding:** We would like to acknowledge the financial support of the National Key R&D Program of China (Honghui Zhu) (2019YFC1606300), Guangdong Provincial Key Laboratory (Yu Ding) (2020B121201009), the Key Research and Development Program of Guangdong Province (Xiaojuan Yang) (2018B020205001), and GDAS’ Special Project of Science and Technology Development (Qingping Wu) (2020GDASYL-2020041002).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Boucher, H.W.; Corey, G.R. Epidemiology of methicillin-resistant \textit{Staphylococcus aureus}. \textit{Clin. Infect. Dis.} \textbf{2008}, \textit{46} (Suppl. 5), S344–S349. [CrossRef] [PubMed]
2. Hennekinne, J.A.; De Buyser, M.L.; Dragacci, S. \textit{Staphylococcus aureus} and its food poisoning toxins: Characterization and outbreak investigation. \textit{FEMS Microbiol. Rev.} \textbf{2012}, \textit{36}, 815–836. [CrossRef] [PubMed]
3. Fetsch, A.; Contzen, M.; Hartelt, K.; Kleiser, A.; Maassen, S.; Rau, J.; Kraushaar, B.; Layer, F.; Strommenger, B. \textit{Staphylococcus aureus} food-poisoning outbreak associated with the consumption of ice-cream. \textit{Int. J. Food Microbiol.} \textbf{2014}, \textit{187}, 1–6. [CrossRef] [PubMed]
4. Vaiyapuri, M.; Joseph, T.C.; Rao, B.M.; Lalitha, K.V.; Prasad, M.M. methicillin-resistant \textit{Staphylococcus aureus} in seafood: Prevalence, laboratory detection, clonal nature, and control in seafood chain. \textit{J. Food Sci.} \textbf{2019}, \textit{84}, 3341–3351. [CrossRef] [PubMed]
5. Paudyal, N.; Anihouvi, V.; Hounhouigan, J.; Matsheka, M.I.; Sekwati-Monang, B.; Amoa-Awua, W.; Atter, A.; Ackah, N.B.; Mbugua, S.; Asagbra, A.; et al. Prevalence of foodborne pathogens in food from selected African countries—A meta-analysis. \textit{Int. J. Food Microbiol.} \textbf{2017}, \textit{249}, 35–43. [CrossRef]
6. Chajek-Wierzchowska, W.; Zadernowska, A.; Nalepa, B.; Sierpińska, M.; Laniewska-Trohenik, L. Retail ready-to-eat food as a potential vehicle for *Staphylococcus* spp. harboring antibiotic resistance genes. *J. Food Prot.* 2014, 77, 993–998. [CrossRef]

7. Chajek-Wierzchowska, W.; Zadernowska, A.; Nalepa, B.; Sierpińska, M.; Laniewska-Trohenik, L. Coagulase-negative *staphylococcus* (CoNS) isolated from ready-to-eat food of animal origin—phenotypic and genotypic antibiotic resistance. *Food Microbiol.* 2015, 46, 222–226. [CrossRef]

8. Ou, Q.; Zhou, J.; Lin, D.; Bai, C.; Zhang, T.; Lin, J.; Zheng, H.; Wang, X.; Ye, J.; Ye, X.; et al. A large meta-analysis of the global prevalence rates of *S. aureus* and MRSA contamination of milk. *Crit. Rev. Food Sci. Nutr.* 2018, 58, 2213–2228. [CrossRef]

9. Forrest, G.N.; Tamura, K. Rifampin combination therapy for non-mycobacterial infections. *Clin. Microbiol. Rev.* 2010, 23, 14–34. [CrossRef]

10. Deresinski, S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant *Staphylococcus aureus* infections. *Clin. Infect. Dis.* 2009, 49, 1072–1079. [CrossRef]

11. Aubry-Damon, H.; Soussy, C.J.; Courvalin, P. Characterization of mutations in the *rpoB* gene that confer rifampin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 1998, 42, 2590–2594. [CrossRef]

12. Hellmark, B.; Söderquist, B.; Unemo, M. Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the *rpoB* gene. *Eur. J. Clin. Microbiol.* 2009, 28, 183–190. [CrossRef]

13. Zimmerli, W.; Sendi, P. Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections. *Antimicrob. Agents Chemother.* 2019, 63, e01746-18. [CrossRef]

14. Telenti, A.; Imboden, P.; Marchesi, F.; Lowrie, D.; Cole, S.; Colston, M.J.; Matter, L.; Schopfer, K.; Bodmer, T. Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet* 1993, 341, 647–650. [CrossRef]

15. Wi, Y.M.; Greenwood-Quaintance, K.E.; Brinkman, C.L.; Lee, J.Y.H.; Howden, B.P.; Patel, R. Rifampicin resistance in *Staphylococcus aureus* isolated from retail vegetables in China. 2019, 236–250. [CrossRef] [PubMed]

16. Matsuo, M.; Hishinuma, T.; Katayama, Y.; Cui, L.; Kapi, M.; Hiramatsu, K. Mutation of RNA polymerase beta subunit (*rpoB*) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. *Antimicrob. Agents Chemother.* 2011, 55, 4188–4195. [CrossRef]

17. Watanabe, Y.; Cui, L.; Katayama, Y.; Kozue, K.; Hiramatsu, K. Impact of *rpoB* mutations on reduced vancomycin susceptibility in *Staphylococcus aureus*. *J. Clin. Microbiol.* 2011, 49, 2680–2684. [CrossRef]

18. Cui, L.; Issi, T.; Fukuda, M.; Ochiai, T.; Neoh, H.M.; Camargo, I.L.; Watanabe, Y.; Shoji, M.; Hishinuma, T.; Hiramatsu, K. An *rpoB* mutation confers dual heteroresistance to daptomycin and vancomycin in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 2010, 54, 5222–5233. [CrossRef] [PubMed]

19. Aiba, Y.; Katayama, Y.; Hishinuma, T.; Murakami-Kuroda, H.; Cui, L.; Hiramatsu, K. Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-conformational conversion of β-lactam resistance in methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 2013, 57, 4861–4871. [CrossRef]

20. Guéritot, R.; Gonçalves da Silva, A.; Monk, I.; Giuliieri, S.; Tomita, T.; Alison, E.; Porter, J.; Pidot, S.; Gao, W.; Peleg, A.Y.; et al. Convergent evolution driven by rifampin exacerbates the global burden of drug-resistant *Staphylococcus aureus*. mSphere 2018, 3, e00550-17. [CrossRef] [PubMed]

21. Wu, S.; Huang, J.; Wu, Q.; Zhang, J.; Zhang, F.; Yang, X.; Wu, H.; Zeng, H.; Chen, M.; Ding, Y.; et al. *Staphylococcus aureus* isolated from retail food and meat products in China: Incidence, antibiotic resistance and genetic diversity. *Front. Microbiol.* 2018, 9, 2767. [CrossRef]

22. Wu, S.; Huang, J.; Zhang, F.; Wu, Q.; Zhang, J.; Fang, R.; Zeng, H.; Yang, X.; Chen, M.; Wang, J.; et al. Prevalence and characterization of food-related methicillin-resistant *Staphylococcus aureus* (MRSA) in China. *Front. Microbiol.* 2019, 10, 304. [CrossRef]

23. Wu, S.; Huang, J.; Wu, Q.; Zhang, F.; Zhang, J.; Lei, T.; Chen, M.; Ding, Y.; Xue, L. Prevalence and characterization of *Staphylococcus aureus* isolated from retail vegetables in China. *Front. Microbiol.* 2018, 9, 1263. [CrossRef] [PubMed]

24. Yang, X.; Jumei, Z.; Shubo, Y.; Qingping, W.; Weipeng, G.; Jiahui, H.; Shuzhen, C. Prevalence of *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* in retail ready-to-eat foods in China. *Front. Microbiol.* 2016, 7, 816. [CrossRef] [PubMed]

25. Zhang, F.; Wu, S.; Huang, J.; Yang, R.; Zhang, J.; Lei, T.; Dai, J.; Ding, Y.; Xue, L.; Wang, J.; et al. Presence and characterization of a novel cfr-carrying Tn558 transposon derivative in *Staphylococcus delphini* isolated from retail food. *Front. Microbiol.* 2021, 11, 3379. [CrossRef] [PubMed]

26. Wang, C.; Fang, R.; Zhou, B.; Tian, X.; Zhang, X.; Zheng, X.; Zhang, S.; Dong, G.; Cao, J.; Zhou, T. Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant *Staphylococcus aureus* strains selected in vitro. *BMC Microbiol.* 2019, 19, 220. [CrossRef] [PubMed]

27. Xiao, Y.-H.; Giske, C.G.; Wei, Z.-Q.; Shen, P.; Heddini, A.; Li, L.-J. Epidemiology and characteristics of antimicrobial resistance in China. *Drug Resist. Updates* 2011, 14, 236–250. [CrossRef] [PubMed]

28. Şanlıbaba, P. Prevalence, antibiotic resistance, and enterotoxin production of *Staphylococcus aureus* isolated from retail raw beef, sheep, and lamb meat in Turkey. *Int. J. Food Microbiol.* 2021, 361, 109461. [CrossRef]

29. Pereira, V.; Lopes, C.; Castro, A.; Silva, J.; Gibbs, P.; Teixeira, P. Characterization for enterotoxin production, virulence factors, and antibiotic susceptibility of *Staphylococcus aureus* isolates from various foods in Portugal. *Food Microbiol.* 2009, 26, 278–282. [CrossRef]

30. Deresinski, S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant *Staphylococcus aureus* infections. *Clin. Infect. Dis.* 2009, 49, 1072–1079. [CrossRef]
30. Papadopoulos, P.; Papadopoulos, T.; Angelidis, A.S.; Boukouvala, E.; Zdragas, A.; Papa, A.; Hadjichristodoulou, C.; Sergelidis, D. Prevalence of Staphylococcus aureus and of methicillin-resistant S. aureus (MRSA) along the production chain of dairy products in north-western Greece. Food Microbiol. 2018, 69, 43–50. [CrossRef]

31. Aboshikwa, M.; Rowland, G.; Coleman, G. Nucleotide sequence of the Staphylococcus aureus RNA polymerase rpoB gene and comparison of its predicted amino acid sequence with those of other bacteria. Biochim. Biophys. Acta (BBA) Gene Struct. Expr. 1995, 1262, 73–78. [CrossRef]

32. Campbell, E.A.; Korzheva, N.; Mustaev, A.; Murakami, K.; Nair, S.; Goldfarb, A.; Darst, S.A. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001, 104, 901–912. [CrossRef]

33. Jin, D.J.; Gross, C.A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 1988, 202, 45–58. [CrossRef]

34. Lavania, M.; Singh, I.; Turankar, R.P.; Gupta, A.K.; Ahuja, M.; Pathak, V.; Sengupta, U. Enriched whole genome sequencing identified compensatory mutations in the RNA polymerase gene of rifampicin-resistant Mycobacterium leprae strains. Infect. Drug Resist. 2018, 11, 169–175. [CrossRef] [PubMed]

35. Chen, J.-Y.; Fung, C.-P.; Chang, F.-Y.; Huang, L.-Y.; Chang, J.-C.; Siu, L.K. Mutations of the rpoB gene in rifampicin-resistant Streptococcus pneumoniae in Taiwan. J. Antimicrob. Chemother. 2004, 53, 375–378. [CrossRef]

36. Nolte, O.; Müller, M.; Reitz, S.; Ledig, S.; Ehrhard, I.; Sonntag, H.G. Description of new mutations in the rpoB gene of rifampicin-resistant Neisseria meningitidis selected in vitro in a stepwise manner. J. Med. Microbiol. 2003, 52, 1077–1081. [CrossRef]

37. Zhou, W.; Shan, W.; Ma, X.; Chang, W.; Zhou, X.; Lu, H.; Dai, Y. Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China. BMC Microbiol. 2012, 12, 240. [CrossRef]

38. Liang, B.; Mai, J.; Liu, Y.; Huang, Y.; Zhong, H.; Xie, Y.; Deng, Q.; Huang, L.; Yao, S.; He, Y.; et al. Prevalence and characterization of Staphylococcus aureus isolated from women and children in Guangzhou, China. Front. Microbiol. 2018, 9, 2790. [CrossRef]

39. Baines, S.L.; Holt, K.E.; Schultz, M.B.; Seemann, T.; Howden, B.O.; Jensen, S.O.; van Hal, S.J.; Coombs, G.W.; Firth, N.; Powell, D.R.; et al. Convergent adaptation in the dominant global hospital clone ST239 of methicillin-resistant Staphylococcus aureus. mBio 2015, 6, e0080-15. [CrossRef]

40. Murphy, C.K.; Mullin, S.; Osborne, M.S.; van Duzer, J.; Siedlecki, J.; Yu, X.; Kerstein, K.; Cynamon, M.; Rothstein, D.M. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50, 827–834. [CrossRef]

41. Frénay, H.M.; Bunschoten, A.E.; Schouls, L.M.; van Leeuwen, W.J.; Vandenbergroucke-Grauls, C.M.; Verhoef, J.; Mool, F.R. Molecular typing of methicillin-resistant Staphylococcus aureus type strain 8325-4 and of methicillin-susceptible ST398, spa type t571 methicillin-susceptible Staphylococcus aureus strain isolated from women and children in north-western Greece. Food Microbiol. 1995, 1262, 73–78. [CrossRef]

42. David, M.Z.; Siegel, J.; Lowy, F.D.; Zychowski, D.; Taylor, A.; Lee, C.J.; Boylevavra, S.; Daum, R.S. Asymptomatic carriage of sequence type 398, spa type T571 methicillin-susceptible Staphylococcus aureus in an urban jail: A newly emerging, transmissible pathogenic strain. J. Clin. Microbiol. 2013, 51, 2443–2447. [CrossRef]

43. Jin, D.J.; Gross, C.A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 1988, 202, 45–58. [CrossRef]

44. Huang, Y.T.; Liao, C.H.; Chen, S.Y.; Yang, C.J.; Hsu, H.S.; Teng, L.J.; Hsueh, P.R. Characterization of rifampin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China. BMC Microbiol. 2012, 12, 240. [CrossRef]

45. Yu, J.; Wu, J.; Francis, K.P.; Purchio, T.F.; Kadurugamuwa, J.L. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J. Antimicrob. Chemother. 2005, 55, 528–534. [CrossRef] [PubMed]

46. Falagas, M.E.; Bliziotis, I.A.; Fragoulis, K.N. Oral rifampin for eradication of methicillin-resistant Staphylococcus aureus: A systematic review of the evidence from comparative trials. J. Glob. Antimicrob. Resist. 2016, 7, 178–186. [CrossRef]

47. Murphy, C.K.; Mullin, S.; Osborne, M.S.; van Duzer, J.; Siedlecki, J.; Yu, X.; Kerstein, K.; Cynamon, M.; Rothstein, D.M. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50, 827–834. [CrossRef]

48. Wichelsau, T.A.; Schäfer, V.; Brade, V.; Böddinghaus, B. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 1999, 43, 2813–2816. [CrossRef]

49. Cuny, C.; Köck, R.; Witte, W. Livestock associated MRSA (LA-MRSA) and its relevance for humans in Germany. Int. J. Med. Microbiol. 2013, 303, 331–337. [CrossRef]

50. David, M.Z.; Siegel, J.; Lowy, F.D.; Zychowski, D.; Taylor, A.; Lee, C.J.; Boylevavra, S.; Daum, R.S. Asymptomatic carriage of sequence type 398, spa type T571 methicillin-susceptible Staphylococcus aureus in an urban jail: A newly emerging, transmissible pathogenic strain. J. Clin. Microbiol. 2013, 51, 2443–2447. [CrossRef]
53. Argudín, M.A.; Tenhagen, B.A.; Fetsch, A.; Sachsenröder, J.; Käsbohrer, A.; Schroeter, A.; Hammerl, J.A.; Hertwig, S.; Helmuth, R.; Bräunig, J. Virulence and resistance determinants of German Staphylococcus aureus ST398 isolates from nonhuman sources. *Appl. Environ. Microbiol.* **2011**, *77*, 3052–3060. [CrossRef] [PubMed]

54. Gombas, D.E.; Chen, Y.; Clavero, R.S.; Scott, V.N. Survey of *Listeria monocytogenes* in ready-to-eat foods. *J. Food Prot.* **2003**, *66*, 559–569. [CrossRef] [PubMed]

55. Patel, J.B.; Cockerill, F.R., III; Bradford, P.A. *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement*; M100-S25; The Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2015; pp. 128–160.

56. Mick, V.; Domínguez, M.A.; Tubau, F.; Liñares, J.; Pujol, M.; Martin, R. Molecular characterization of resistance to Rifampicin in an emerging hospital-associated methicillin-resistant *Staphylococcus aureus* clone ST228, Spain. *BMC Microbiol.* **2010**, *10*, 68. [CrossRef] [PubMed]

57. Shopsin, B.; Gomez, M.; Montgomery, S.O.; Smith, D.H.; Waddington, M.; Dodge, D.E.; Bost, D.A.; Riehman, M.; Naidich, S.; Kreiswirth, B.N. Evaluation of protein A gene polymorphic region DNA sequencing for typing of *Staphylococcus aureus* strains. *J. Clin. Microbiol.* **1999**, *37*, 3556–3563. [CrossRef]

58. Enright, M.C.; Day, N.P.J.; Davies, C.E.; Peacock, S.J.; Spratt, B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J. Clin. Microbiol.* **2013**, *51*, 306–310. [CrossRef] [PubMed]

59. Zhang, K.; Mcclure, J.A.; Elsayed, S.; Louie, T.; Conly, J.M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome *mec* types I to V in methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* **2005**, *43*, 5026–5033. [CrossRef]